In ₹ Crore except Per Share Latest Annual | PPLPHARMA FY26 | DIVISLAB FY26 | SYNGENE FY26 | GLAND FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | — | 97.31× | 48.79× | ◆ 47.31× | 48.79× | |
| P/B | 3.45× | 14.89× | ◆ 3.20× | 4.69× | 4.69× -27% | |
| EV/EBITDA | 35.05× | 72.47× | ◆ 16.11× | 27.91× | 27.91× +26% | |
| Market Cap | ₹28,134 Cr | ₹2.49L Cr | ₹15,471 Cr | ₹48,604 Cr | ₹48,604 Cr -42% | |
| Growth | ||||||
| Revenue CAGR 3Y | 7.79% | 10.78% | 5.40% | ◆ 21.06% | 10.78% -28% | |
| Revenue CAGR 5Y | — | 8.67% | 11.35% | ◆ 13.18% | 11.35% | |
| Net Income CAGR 3Y | — | ◆ 12.09% | -11.98% | 9.57% | 9.57% | |
| Revenue YoY (latest Q) | 17.39% | ◆ 27.80% | -15.84% | 19.57% | 19.57% -11% | |
| Net Income YoY (latest Q) | 15.07% | ◆ 65.50% | -110.38% | 47.09% | 47.09% -68% | |
| Profitability | ||||||
| EBITDA Margin | 10.39% | ◆ 32.59% | 24.57% | 25.34% | 25.34% -59% | |
| Net Income Margin | -3.68% | ◆ 24.32% | 8.47% | 15.98% | 15.98% -123% | |
| Return on Common Equity | -3.99% | ◆ 15.32% | 6.54% | 9.92% | 9.92% -140% | |
| Return on Capital Employed | 0.68% | ◆ 16.55% | 8.46% | 11.06% | 11.06% -94% | |
| Return on Assets | -1.81% | ◆ 12.82% | 4.49% | 8.21% | 8.21% -122% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 0.67× | ◆ 0.00× | 0.00× | 0.02× | 0.00× | |
| Interest Coverage | 0.27× | ◆ 129.48× | 9.54× | 36.24× | 36.24× -99% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹8,869 Cr | ₹10,560 Cr | ₹3,739 Cr | ₹6,431 Cr | ₹6,431 Cr +38% | |
| Net Income | −₹326 Cr | ₹2,568 Cr | ₹317 Cr | ₹1,027 Cr | ₹1,027 Cr -132% | |
| Total Assets | ₹17,965 Cr | ₹20,033 Cr | ₹7,055 Cr | ₹12,511 Cr | ₹12,511 Cr +44% | |
| EPS | ₹-2.46 | ₹96.75 | ₹7.87 | ₹62.35 | ₹62.35 -104% | |
| Book Value per Share | ₹61.5 | ₹632.49 | ₹120.11 | ₹628.67 | ₹628.67 -90% | |